Richard Jove, Ph.D.

Chair and Professor, Biomedical Sciences
(954) 262-3389

Dr. Richard Jove is director and distinguished research professor of the NSU Cell Therapy Institute, where he leads biomedical research focusing on the discovery and development of cell-based therapies to prevent, treat, and cure debilitating diseases. He joined the College of Allopathic Medicine faculty in 2017 as chair of the Department of Biomedical Sciences.

The primary approaches of the NSU Cell Therapy Institute include immunotherapy of cancer and regenerative medicine for cardiovascular diseases, macular degeneration and other incurable diseases. The research institute is an international collaboration with physicians and scientists at the prestigious Karolinska Institute in Stockholm, Sweden.

Jove began his independent research career in 1988 as an assistant professor at the University of Michigan Medical School in Ann Arbor and was later promoted to associate professor with tenure. Beginning in 1995, he helped establish the Moffitt Comprehensive Cancer Center and Research Institute in Tampa, where he was professor and director of the Molecular Oncology Program and later served as associate director for basic science at the Moffitt Research Institute until 2005.  

From 2005 to 2013, Jove was affiliated with the Beckman Research Institute, part of the City of Hope medical center in Los Angeles. His roles included deputy director of the City of Hope Comprehensive Cancer Center, professor and chair of molecular medicine, and overall director of the Beckman Research Institute, where he focused on developing new therapies for cancer, diabetes, and related diseases.

Jove earned his doctoral degree in molecular biology at Columbia University in 1984 and trained as a post-doctoral fellow at Rockefeller University in New York City. He has published more than 225 scientific articles in biomedical research and received continuous grant funding by the National Institutes of Health (NIH) for more than 25 years. He also is an inventor on more than 50 patents issued and pending.